邢晓莲 李伟荣

[摘要]目的 探討普拉克索联合多巴丝肼片治疗晚期帕金森病的临床效果。方法 选取2016年6月～2017年6月我院收治的80例晚期帕金森病患者作为研究对象，按照随机数字表法分将其为观察组（40例）与对照组（40例）。对照组患者给予多巴丝肼片治疗，观察组患者则给予多巴丝肼片联合普拉克索治疗。比较两组患者的晚期帕金森病控制率，干预前后的简易智能精神状态检查量表评分、汉密尔顿抑郁量表得分、帕金森综合量表评分，治疗后表达能力评分、记忆力评分、阅读和理解评分、时间概念评分及药物不良反应发生率。结果 观察组患者的晚期帕金森病控制率高于对照组，差异有统计学意义（P<0.05）。两组患者干预前的简易智能精神状态检查量表评分、汉密尔顿抑郁量表得分、帕金森综合量表评分比较，差异无统计学意义（P>0.05）；两组患者干预后的简易智能精神状态检查量表评分高于干预前，汉密尔顿抑郁量表得分、帕金森综合量表评分均低于干预前，差异有统计学意义（P<0.05）；观察组患者干预后的的简易智能精神状态检查量表评分高于对照组，汉密尔顿抑郁量表得分、帕金森综合量表评分均低于对照组，差异有统计学意义（P<0.05）。观察组患者治疗后的表达能力评分、记忆力评分、阅读和理解评分、时间概念评分均高于对照组，差异有统计学意义（P<0.05）。两组患者的不良反应总发生率比较，差异无统计学意义（P>0.05）。结论 多巴丝肼片联合普拉克索治疗晚期帕金森病，效果确切，可有效改善临床症状，改善患者认知功能、抑郁情绪和精神状态，且无严重不良反应，安全有效，值得推广应用。

[关键词]多巴丝肼片；普拉克索；晚期帕金森病；应用效果

[中图分类号] R749 [文献标识码] A [文章编号] 1674-4721（2018）9（a）-0137-04

[Abstract] Objective To investigate the clinical effect of Pramipexole combined with Levodopa and Benserazide Hydrochloride Tablets in the treatment of advanced Parkinson′s disease. Methods A total of 80 patients with advanced Parkinson′s disease who were admitted to our hospital from June 2016 to June 2017 were selected as the study subjects. According to the random number table method， they were divided into observation group （40 cases） and control group （40 cases）. The control group was treated with Levodopa and Benserazide Hydrochloride Tablets alone， and the observation group was given Pramipexole combined with Levodopa and Benserazide Hydrochloride Tablets. The control rate of advanced Parkinson′s disease， the simple intelligent mental state examination scale scores， the Hamilton depression scale scores， and the Parkinson′s comprehensive scale scores before and after the intervention， expression ability scores， the memory scores， the reading and understanding scores， time concept scores after treatment and incidence of adverse drug reactions were compared between two groups. Results The control rate of Parkinson′s disease in the observation group was significantly higher than that in the control group， and the difference was statistically significant （P<0.05）. There were no significant differences in the simple intelligent mental state examination scale scores， the Hamilton depression scale scores， and the Parkinson′s comprehensive scale scores before intervention between two groups （P>0.05）. The scores of the simple intelligent mental state examination scale after the intervention in two groups were higher than those before the intervention， the scores of the Hamilton depression scale and the Parkinson′s comprehensive scale were lower than those before the intervention， and the differences were statistically significant （P<0.05）. The scores of the simple intelligent mental state examination scale after the intervention in the observation group were higher than those in the control group， the scores of the Hamilton depression scale and the Parkinson′s comprehensive scale were lower than those in the control group， and the differences were statistically significant （P<0.05）. The scores of expression ability， memory， reading and understanding， and time concept of the observation group were higher than those of the control group， and the differences were statistically significant （P<0.05）. There was no significant difference in the incidence of adverse reactions between two groups （P>0.05）. Conclusion Pramipexole combined with Levodopa and Benserazide Hydrochloride Tablets has a definite effect in the treatment of advanced Parkinson′s disease. It can effectively improve the clinical symptoms， improve the patients′ cognitive function， depressive mood and mental state， and has no serious adverse reactions， which is safe and effective and worthy of promotion and application.

[Key words] Levodopa and Benserazide Hydrochloride Tablets； Pramipexole； Advance Parkinson′s disease； Application effect

帕金森病患者近年来越来越多，其和人口老龄化之间有密切的关系[1]，是老年人常见的神经系统渐进性、退行性病变，目前无根治方法。晚期帕金森病患者可出现肌强直、静止性震颤、认知和劲射状态异常、步态和姿势异常、感觉、睡眠障……